ERBB2 and colorectal cancer: However, concurrent treatment with anti-HER2 therapy and anti-EGFR therapy, may overcome this resistance: pertuzumab and lapatinib has demonstrated meaningful activity in patient-derived xenografts of colorectal cancer resistant to cetuximab [95,96].